Lux Biosciences to present on LX211 at 2009 AAO annual conference

Oct 21 2009

Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company’s experimental drug LX211 (LUVENIQ™; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco. Lux Biosciences plans to file an NDA and MAA for marketing approvals of LX211 in the United States and Europe, respectively around year-end 2009. If approved, LX211 may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions previously inevitably associated with either severe vision loss or substantial morbidity from steroid use.

Several presentations during AAO will discuss the results of the completed LUMINATE pivotal studies for LX211 and its use in active and clinically quiescent noninfectious uveitis. These presentations include:

Sunday October 25^th:

• American Uveitis Society Meeting, 9-10:30 pm, JW Marriott
  “Luveniq for Sight-Threatening Non-Infectious Uveitis: Results of the LUMINATE trials”
  Presenter: Dr. C. Stephen Foster, M.D., head of the Ocular Immunology and Uveitis Foundation, Founder and President of the Massachusetts Eye Research and Surgery Institution and Clinical Professor of Ophthalmology at Harvard Medical School.

Monday October 26

• Session: Luveniq (LX211/Voclosporin) as Corticosteroid-Sparing Therapy in Clinically Quiescent Sight-Threatening Noninfectious Uveitis: Results of the LX221-02 Study of the LUMINATE Clinical Program.
  Program # PA026 8:50 – 8:57 am, Moscone Center – West 2006
  Presenter: Bahram Bodaghi, M.D., Ph.D., Pitié Salpétrière Hospital Paris, France

• Session: Voclosporin (LX211) as Corticosteroid-Sparing Therapy for Posterior Active Sight-Threatening Noninfectious Uveitis: Results of the LX211-01 Study of the LUMINATE Program.
  Program # PA027 9:00 – 9:07 am, Moscone Center – West 2006
  Presenter: Quan D. Nguyen, M.D., of the Wilmer Eye Institute at The Johns Hopkins University, Baltimore, MD

http://www.luxbio.com